These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs. Thomas D; Ali Z; Zachariah S; Sundararaj KGS; Van Cuyk M; Cooper JC Am J Cardiovasc Drugs; 2017 Oct; 17(5):343-346. PubMed ID: 28353025 [TBL] [Abstract][Full Text] [Related]
6. Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. Tacconelli S; Bruno A; Grande R; Ballerini P; Patrignani P Expert Opin Drug Saf; 2017 Jul; 16(7):791-807. PubMed ID: 28569569 [TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. Hennekens CH; Borzak S J Cardiovasc Pharmacol Ther; 2008 Mar; 13(1):41-50. PubMed ID: 18287589 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966 [TBL] [Abstract][Full Text] [Related]
9. Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned? Minhas D; Nidhaan A; Husni ME Rheum Dis Clin North Am; 2023 Feb; 49(1):179-191. PubMed ID: 36424024 [TBL] [Abstract][Full Text] [Related]
10. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Maillard M; Burnier M Expert Opin Drug Saf; 2006 Jan; 5(1):83-94. PubMed ID: 16370958 [TBL] [Abstract][Full Text] [Related]
11. COX-2 selective inhibitors in the treatment of osteoarthritis. Laine L; White WB; Rostom A; Hochberg M Semin Arthritis Rheum; 2008 Dec; 38(3):165-87. PubMed ID: 18177922 [TBL] [Abstract][Full Text] [Related]
13. COXIBs, CINODs and H₂S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs. Fiorucci S; Distrutti E Curr Med Chem; 2011; 18(23):3494-505. PubMed ID: 21756233 [TBL] [Abstract][Full Text] [Related]
14. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Hochberg MC Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069 [TBL] [Abstract][Full Text] [Related]
15. The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks. Cairns JA Can J Cardiol; 2007 Feb; 23(2):125-31. PubMed ID: 17311118 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. McGettigan P; Henry D JAMA; 2006 Oct; 296(13):1633-44. PubMed ID: 16968831 [TBL] [Abstract][Full Text] [Related]